OppenheimerFunds Inc. Sells 7,388 Shares of Shire PLC (NASDAQ:SHPG)

OppenheimerFunds Inc. cut its holdings in Shire PLC (NASDAQ:SHPG) by 5.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,882 shares of the biopharmaceutical company’s stock after selling 7,388 shares during the period. OppenheimerFunds Inc.’s holdings in Shire were worth $23,274,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Rockefeller Capital Management L.P. acquired a new stake in shares of Shire in the first quarter valued at approximately $113,097,000. First Trust Advisors LP raised its holdings in shares of Shire by 1.9% in the second quarter. First Trust Advisors LP now owns 350,477 shares of the biopharmaceutical company’s stock valued at $59,161,000 after purchasing an additional 6,682 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Shire in the second quarter valued at approximately $55,664,000. Delek Group Ltd. raised its holdings in shares of Shire by 101.0% in the first quarter. Delek Group Ltd. now owns 252,750 shares of the biopharmaceutical company’s stock valued at $37,797,000 after purchasing an additional 127,000 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Shire by 41.1% in the first quarter. Millennium Management LLC now owns 244,202 shares of the biopharmaceutical company’s stock valued at $36,481,000 after purchasing an additional 71,073 shares during the last quarter. Institutional investors own 17.84% of the company’s stock.

Shares of SHPG opened at $172.84 on Tuesday. The firm has a market cap of $55.10 billion, a P/E ratio of 11.38, a PEG ratio of 1.61 and a beta of 1.19. Shire PLC has a 1-year low of $123.73 and a 1-year high of $182.36. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.02 and a current ratio of 1.55.

Shire (NASDAQ:SHPG) last issued its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.67 by $0.21. Shire had a net margin of 31.06% and a return on equity of 13.22%. The business had revenue of $3.92 billion for the quarter. During the same quarter in the previous year, the firm posted $3.73 earnings per share. Shire’s quarterly revenue was up 4.6% on a year-over-year basis. On average, analysts predict that Shire PLC will post 15.27 earnings per share for the current year.

The business also recently disclosed a dividend, which will be paid on Friday, October 19th. Shareholders of record on Friday, September 7th will be given a dividend of $0.168 per share. The ex-dividend date is Thursday, September 6th. Shire’s dividend payout ratio (DPR) is 2.24%.

SHPG has been the topic of a number of recent research reports. Sanford C. Bernstein downgraded shares of Shire from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 4th. Royal Bank of Canada set a $188.00 price objective on shares of Shire and gave the company a “buy” rating in a report on Thursday, July 19th. Evercore ISI downgraded shares of Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price objective on the stock. in a report on Tuesday, September 4th. BidaskClub upgraded shares of Shire from a “sell” rating to a “hold” rating in a report on Thursday, September 13th. Finally, ValuEngine downgraded shares of Shire from a “hold” rating to a “sell” rating in a report on Thursday, September 6th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $196.73.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

See Also: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply